Levetiracetam in clinical practice: Long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center

Epilepsy and Behavior

Volumn 10, Issue 2, 2007, Pages 296-303

  Bootsma, H P R ^a   Ricker, L ^b   Diepman, L ^a   Gehring, J ^a   Hulsman, J ^a   Lambrechts, D ^a   Leenen, L ^a   Majoie, M ^a   Schellekens, A ^a   de Krom, M ^b   Aldenkamp, A P ^a,b  

^a EPILEPSY CENTER KEMPENHAEGHE   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antiepileptics; Cognitive function; Levetiracetam; Long term retention; Side effects of antiepileptic drugs

Indexed keywords

ACETAZOLAMIDE; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

ADD ON THERAPY; ADOLESCENT; ADULT; AGGRESSION; AGITATION; APATHY; ARTICLE; ASTHENIA; ATAXIA; BEHAVIOR DISORDER; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIPLOPIA; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG WITHDRAWAL; ENDOCRINE DISEASE; EPILEPSY; EYE DISEASE; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; INSOMNIA; IRRITABILITY; KAPLAN MEIER METHOD; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION SYSTEM; MONOTHERAPY; MOOD DISORDER; NETHERLANDS; PATIENT REFERRAL; PREDICTION; REMISSION; SIDE EFFECT; SKIN DISEASE; SOMNOLENCE; TERTIARY HEALTH CARE;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; EPILEPSY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; MALE; MENTAL DISORDERS; MIDDLE AGED; PIRACETAM; REFERRAL AND CONSULTATION; SEIZURES; SURVIVAL ANALYSIS;

EID: 33947265900     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2006.11.016     Document Type: Article

References (26)

1. In: Stefan H., Krämer G., and Mamoli B. (Eds). Challenge epilepsy: new antiepileptic drugs (1998), Blackwell Science, Berlin
2. Lynch B.A., Lambeng N., Nocka K., et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA 101 (2004) 9861-9866
3. Patsalos P.N. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther 85 (2000) 77-85
4. Cereghino J.J., Biton V., Abou-Khalil B., Dreifuss F., Gauer L.J., and Leppik I. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 55 (2000) 236-242
5. Ben-Menachem E., Falter U., and for the European Levetiracetam Study Group. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selector study evaluating monotherapy. Epilepsia 41 (2000) 1276-1283
6. Shorvon S.D., Lowenthal A., Janz D., Bielen R., Loiseau P., and For the European Levetiracetam Study Group. Multicenter double-blind, randomized placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. Epilepsia 41 (2000) 1179-1186
7. Walker M.C., and Sander J.W.A.S. Difficulties in extrapolating from clinical trial data to clinical practice: the case of antiepileptic drugs. Neurology 49 (1997) 333-337
8. Walker M.C., and Sander J.W.A.S. Topiramate. Seizure 5 (1996) 199-204
9. Walker M.C., and Sander J.W. The impact of new antiepileptic drugs on the prognosis of epilepsy: seizure freedom should be the ultimate goal. Neurology 46 (1996) 912-914
10. Nicolson A., Lewis S.A., and Smith D.F. A prospective analysis of the outcome of levetiracetam in clinical practice. Neurology 63 (2004) 568-570
11. Depondt C., Yuen A.W.C., Bell G.S., et al. The long term retention of levetiracetam in a large cohort of patients with epilepsy. J Neurol Neurosurg Psychiatry 77 (2006) 101-103
12. Ketter T.A., Post R.M., and Theodore W.H. Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. Neurology 53 Suppl. 2 (1999) S53-S67
13. Roberts G.M.P., Majoie H.J.M., Leenen L.A.M., et al. Ketter's hypothesis of the mood effects of antiepileptic drugs coupled to the mechanism of action of topiramate and levetiracetam. Epilepsy Behav 6 (2005) 366-372
14. Kaplan E.L. Non-parametric estimation from incomplete observations. Am Stat Assoc J 53 (1958) 457-481
15. Ben-Menachem E., and Gilland E. Efficacy and tolerability of levetiracetam during 1-year follow-up in patients with refractory epilepsy. Seizure 12 (2003) 131-135
16. Keller M.W., Smith D.F., Stockton P.A., and Chadwick D.W. Topiramate in clinical practice: first year's postlicensing experience in a specialist epilepsy clinic. J Neurol Neurosurg Psychiatry 66 (1999) 759-763
17. Wong I.C.K. New antiepileptic drugs: study suggests that a quarter of patients will still be taking the new drugs after six years. Br Med J 314 (1997) 603-604
18. Abou-Khalil B., and Schaich L. Long-term efficacy of levetiracetam for partial seizures. Seizure 14 (2005) 577-585
19. Brodtkorb E., Klees T.M., Nakken K.O., Lossius R., and Johannessen S.I. Levetiracetam in adult patients with and without learning disability: focus on behavioral adverse effects. Epilepsy Behav 5 (2004) 231-235
20. Krakow K., Walker M., Otoul C., and Sander J.W.A.S. Long-term continuation of levetiracetam in patients with refractory epilepsy. Neurology 56 (2001) 1772-1774
21. Kumar S.P., and Smith P.E.M. Levetiracetam as add-on therapy in generalised epilepsies. Seizure 13 (2004) 475-477
22. Betts T., Waegemans T., and Crawford P. A multicentre, double-blind randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy. Seizure 9 (2000) 80-87
23. Rugino T.A., and Samsock T.C. Levetiracetam in autistic children: an open label study. J Dev Behav Pediatr 4 (2002) 225-230
24. Reijs R., Aldenkamp A.P., and De Krom M. Mood effects of antiepileptic drugs. Epilepsy Behav 5 Suppl. 1 (2004) S66-S76
25. White J.R., Walczak T.S., Leppik L.E., et al. Discontinuation of levetiracetam because of behavioral side effects: a case-control study. Neurology 61 (2003) 1218-1221
26. Privitera M. Efficacy of levetiracetam: a review of three pivotal clinical trials. Epilepsia 42 Suppl. 4 (2001) 31-35